EMA (European Medicines Agency)
AFSTYLA can be used for all age groups.
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) and evaluate the overall safety profile of idelalisib...
Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran
To investigate safety, tolerability, PK and PD of BI 655075 and to establish the BI 655075 dose(s) effective to reverse...
The main objective of the study is to assess the pharmacokinetics of FACTOR X after a single dose of 25IU/kg....
Visual acuity at near improves in children with Down syndrome using bifocals
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
The purpose of this study is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Rivaroxaban.
Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?
The aim of this study was to compare the efficacy, safety, and cost-effectiveness of 3-factor prothrombin complex concentrate vs 4-factor prothrombin complex concentrate in trauma patients requiring reversal of oral anticoagulants.
Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers.
It was hypothesized that the four-factor prothrombin complex concentrate (4F-PCC) Kcentra 25 unit/kg would reverse impairment of thrombin generation in healthy volunteers dosed with apixaban to steady state.
Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
Purpose: Nonacog alfa, a recombinant factor IX (FIX) product, is used for FIX replacement in the treatment and prevention of...
This guideline covers the assessment for and management of blood transfusions in adults, young people and children over 1 year...
The aim of this guideline is to provide recommendations for the haematological management of major haemorrhage in any clinical situation,...
The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology
The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of patients...
|Agency product number||EMEA/H/C/004075|
|Date First Approved||04-01-2017|
|Type||Medicinal product subject to restricted medical prescription|
|Marketing authorisation holder||CSL Behring GmbH|